- Home
- Companies
- north america
- cancer screening
Show results for
Refine by
Cancer Screening Suppliers In North America
50 companies found
based inNew York, NEW YORK (USA)
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We have the brightest people in the industry and believe that their diverse ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
based inEatontown, NEW JERSEY (USA)
Immunostics offers a broad portfolio of performance-driven diagnostics solutions that provide more effective ways to assist in the diagnosis of a disease. Our products offer the right balance of science, technology and practicality across the ...
Greater sensitivity than traditional guaiac-based methods. Increased specificity to lower GI bleeding makes hema-screen SPECIFIC GOLD an ideal tool for colon cancer ...
based inSunnyvale, CALIFORNIA (USA)
Olympia Diagnostics is an In Vitro Diagnostics (IVD) company focusing on development and commercialization of the most advanced breakthrough products for cancer diagnosis and prognosis. We developed a proprietary biomarker discovery platform to ...
A diagnostic test kit quantitatively measures the expression levels of a panel of prostate cancer risk-associated biomarkers in patient urine sample or biopsy tissue sample to distinguish high-risk and aggressive prostate cancer needing immediate ...
based inBeverly, MASSACHUSETTS (USA)
Cellanyx is a growth stage emerging biotech advancing proprietary phenotypic (appearance and dynamics) biomarker tests based on Machine Vision and AI-driven analysis of live single tumor cells to improve risk-stratification and shared clinical ...
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no ...
based inSeattle, WASHINGTON (USA)
SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The ...
based inSan Antonio, TEXAS (USA)
Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company formed to commercialize a new modality in cancer screening and diagnosis called opto-acoustic imaging. A strong, experienced management team and nationally ...
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
This highly automated testing instrument is manufactured to company specifications by Hamilton Company, producing an accurate diagnosis without human interpretation. Hamilton has been as strong supporter of OTraces, having provided all ...
based inBoston, MASSACHUSETTS (USA)
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of ...
based inFort Myers, FLORIDA (USA)
NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with ...
Histology, tissue staining using the latest in automated staining platforms, and digital pathology services form the foundation of a strong anatomic pathology program. Anatomic Pathology at NeoGenomics offers in-house comprehensive diagnostic ...
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA ...
based inDoylestown, PENNSYLVANIA (USA)
Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality. Our proprietary ...
based inNew York, NEW YORK (USA)
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management ...
The science behind miR’s prostate and bladder cancer detection and classification technology that can help give healthcare providers, patients, and payors the greatest confidence in test results and care ...
based inSan Diego, CALIFORNIA (USA)
OnsiteGene Inc. is a biomedical technology company spearheading the new era of super-fast on-site genetic testing in minutes based on a novel integrated sample prep and qPCR process. OnsiteGene is located in San Diego, California, USA. OnsiteGene's ...
based inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for ...
based inGaithersburg, MARYLAND (USA)
20/20 GeneSystems Inc. develops and commercializes diagnostic tests for the early detection of cancer to improve outcomes of people at high risk for specific types of cancers. It offers blood tests for use in the United States to aid in the early ...
based inCarlsbad, CALIFORNIA (USA)
We are a global medical technology company committed to providing peace of mind to patients and physicians alike through the use of MBI and PET as secondary screening and diagnostic tools. Both the LumaGEM ® Molecular Breast Imaging (MBI) system and ...
The LumaGEM® Molecular Breast Imaging system’s patented mounting mechanism allows the use of light breast immobilization for greater patient comfort during breast cancer imaging exam. The LumaGEM MBI system for breast cancer imaging ...
based inDurham, NORTH CAROLINA (USA)
Altis Biosystems’ mission is to develop, manufacture, and sell innovative services and research tools to reduce costs and accelerate drug development with in vitro platforms that more accurately reflect native human biology. Altis Biosystems is a ...
based inOakland, CALIFORNIA (USA)
xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform’s portals, xINFORM for patients, and xDECIDE for providers, show scientific and medical ...
xCures’ patient-centric focus ensures that advanced cancer patients continuously engage with the xCures platform. Patients and their treating physicians receive decision support and access to leading therapeutics and diagnostics in return for ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...